Additionally, CD 19-directed CAR-T cell therapy could prove to be an effective therapy in RUNX1 mutant CML BC with aberrant expression of CD19 cells. Here, RUNX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.